Floatz logo

Xmab808

Castration-resistant Prostate Cancer

Xencor, Inc.Phase 1Active
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

229 Active assets in the Castration-resistant Prostate Cancer cohort.

Asset / SponsorPhaseRating
Darolutamide
Bayer
Phase 4BBB
Enzalutamide
Prostate Cancer Clinical Trials Consortium
Phase 4BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Ding-Wei Ye
Phase 4BBB
Darolutamide
Bayer
Phase 3BB
Bms-907351
Rana McKay, MD
Phase 3BB

View all 50 →

Same molecule, other indications

Xmab808 is also rated in:

nonpapillary renal cell carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
ovarian carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
urothelial carcinomaDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →